Truveta Secures $320 Million for Largest Genetic Database
Summary
Truveta, a US-based medical data research company, announced a significant investment on Monday. According to Truveta CEO Terry Myerson, this initiative is set to revolutionise drug discovery and improve patient care.Genetic sequencing can identify patient predispositions for conditions like Alzheimers, sickle cell disease, and cancer. This knowledge can accelerate drug development and improve the targeting of existing therapies.Regeneron will oversee genome sequencing, while Truveta will store the genetic data on its platform for analysis. The healthcare partners involved will request patient consent to analyse leftover lab specimens, linking them to anonymous medical records.Regeneron executive Aris Baras highlighted the projects scope: The scale and diversity of the Truveta Genome Project will enable us to explore the complex interplay between genetics and health in unprecedented detail.Myerson stated that Truvetas project is expected to surpass the diversity and size of the current largest genetic databases, including the US National Institutes of Healths All of Us Research Program, with 850,000 participants, and the UK Biobank, with 500,000 participants.The company plans to reimburse healthcare providers when other entities purchase access to its anonymous patient data. Myerson emphasised this model as an incentive to ensure the projects success.Microsoft, a prior investor in Truveta, will supply the cloud infrastructure for the initiative through its Azure platform.This groundbreaking collaboration could mark a significant step forward in genetic research, enabling deeper insights into the relationship between genetics and health.